JP7384903B2 - フルベストラントのプロドラッグ - Google Patents

フルベストラントのプロドラッグ Download PDF

Info

Publication number
JP7384903B2
JP7384903B2 JP2021515306A JP2021515306A JP7384903B2 JP 7384903 B2 JP7384903 B2 JP 7384903B2 JP 2021515306 A JP2021515306 A JP 2021515306A JP 2021515306 A JP2021515306 A JP 2021515306A JP 7384903 B2 JP7384903 B2 JP 7384903B2
Authority
JP
Japan
Prior art keywords
optionally substituted
aryl
group
cycloalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021515306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525278A5 (https=
JP2021525278A (ja
JPWO2019224790A5 (https=
Inventor
プロヒト，パーヴァ・ヨーゲシチャンドラ
ブラームクシャトリヤ，パシック・サバッシュチャンドラ
ゴスワミ，ヴィシャギリ・ガンヴァントギリ
Original Assignee
ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー filed Critical ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー
Publication of JP2021525278A publication Critical patent/JP2021525278A/ja
Publication of JP2021525278A5 publication Critical patent/JP2021525278A5/ja
Publication of JPWO2019224790A5 publication Critical patent/JPWO2019224790A5/ja
Priority to JP2023191446A priority Critical patent/JP7653092B2/ja
Application granted granted Critical
Publication of JP7384903B2 publication Critical patent/JP7384903B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2021515306A 2018-05-24 2019-05-24 フルベストラントのプロドラッグ Active JP7384903B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023191446A JP7653092B2 (ja) 2018-05-24 2023-11-09 フルベストラントのプロドラッグ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201821019542 2018-05-24
IN201821019542 2018-05-24
IN201821047939 2018-12-18
IN201821047939 2018-12-18
PCT/IB2019/054315 WO2019224790A2 (en) 2018-05-24 2019-05-24 Prodrugs of fulvestrant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191446A Division JP7653092B2 (ja) 2018-05-24 2023-11-09 フルベストラントのプロドラッグ

Publications (4)

Publication Number Publication Date
JP2021525278A JP2021525278A (ja) 2021-09-24
JP2021525278A5 JP2021525278A5 (https=) 2022-06-13
JPWO2019224790A5 JPWO2019224790A5 (https=) 2022-06-13
JP7384903B2 true JP7384903B2 (ja) 2023-11-21

Family

ID=68615936

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021515306A Active JP7384903B2 (ja) 2018-05-24 2019-05-24 フルベストラントのプロドラッグ
JP2023191446A Active JP7653092B2 (ja) 2018-05-24 2023-11-09 フルベストラントのプロドラッグ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023191446A Active JP7653092B2 (ja) 2018-05-24 2023-11-09 フルベストラントのプロドラッグ

Country Status (6)

Country Link
US (1) US20210253626A1 (https=)
EP (1) EP3801553B1 (https=)
JP (2) JP7384903B2 (https=)
AU (1) AU2019274815B2 (https=)
CA (1) CA3101421C (https=)
WO (1) WO2019224790A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023503898A (ja) * 2019-11-24 2023-02-01 カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ
JP2024016210A (ja) * 2018-05-24 2024-02-06 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202146405A (zh) * 2020-02-25 2021-12-16 日商大日本住友製藥股份有限公司 Cdk9抑制劑前體藥物及內封其之脂質體
WO2022034587A1 (en) * 2020-08-10 2022-02-17 Tnik Therapeutics Ltd Traf2- AND Nck-INTERACTING KINASE (TNIK) INHIBITORS AND USES THEREOF
WO2023027032A1 (ja) * 2021-08-23 2023-03-02 住友ファーマ株式会社 自己分解型ｃｄｋ９阻害剤プロドラッグ及びそれを内封するリポソーム
AU2022377397A1 (en) * 2021-10-29 2024-06-13 Kashiv Biosciences, Llc Inectable pharmaceutical composition for treatment of breast cancer
CN117957238A (zh) * 2021-12-06 2024-04-30 江苏亚虹医药科技股份有限公司 氟维司群衍生物及其制备方法和医药用途
EP4444318A4 (en) * 2021-12-06 2026-01-28 Amneal Pharmaceuticals Llc COMPOUNDS FOR CANCER TREATMENT
CN119751533B (zh) * 2025-03-10 2026-01-13 山东大学 一种基于雌甾三烯结构的雌激素受体蛋白靶向降解嵌合体衍生物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528919A (ja) 2000-04-05 2003-09-30 アストラゼネカ アクチボラグ 抵抗性乳癌の治療におけるフルベストラントの使用
CN103421069A (zh) 2013-05-23 2013-12-04 中国海洋大学 氟维司群磷酸酯衍生物及其制备方法和应用
JP2015511606A (ja) 2012-03-31 2015-04-20 リポント ファーマシューティカルズ インコーポレイテッド 乳酸エステルをベースとするフルベストラント又はその誘導体の油性製剤およびその製造方法
CN108159055A (zh) 2018-01-04 2018-06-15 西安力邦医药科技有限责任公司 治疗乳腺癌的长效递药系统、其制备方法及应用
WO2019050850A1 (en) 2017-09-05 2019-03-14 Primetime Life Sciences, Llc BIGUANIDINE DERIVATIVES OF THERAPEUTIC AGENTS, AND PREPARATION METHODS AND METHODS OF USING SAME

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CA2909418A1 (en) * 2013-04-18 2014-10-23 Xi'an Libang Pharmaceutical Technology Co., Ltd. Ester derivative of 7-.alpha.-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)n onyl]-estra-1,3,5(10)-triene-3,17.beta.-diol having anticancer activity and preparation method thereof
US10112962B2 (en) 2014-07-02 2018-10-30 Xavier University Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528919A (ja) 2000-04-05 2003-09-30 アストラゼネカ アクチボラグ 抵抗性乳癌の治療におけるフルベストラントの使用
JP2015511606A (ja) 2012-03-31 2015-04-20 リポント ファーマシューティカルズ インコーポレイテッド 乳酸エステルをベースとするフルベストラント又はその誘導体の油性製剤およびその製造方法
CN103421069A (zh) 2013-05-23 2013-12-04 中国海洋大学 氟维司群磷酸酯衍生物及其制备方法和应用
WO2019050850A1 (en) 2017-09-05 2019-03-14 Primetime Life Sciences, Llc BIGUANIDINE DERIVATIVES OF THERAPEUTIC AGENTS, AND PREPARATION METHODS AND METHODS OF USING SAME
CN108159055A (zh) 2018-01-04 2018-06-15 西安力邦医药科技有限责任公司 治疗乳腺癌的长效递药系统、其制备方法及应用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024016210A (ja) * 2018-05-24 2024-02-06 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ
JP7653092B2 (ja) 2018-05-24 2025-03-28 シヴァンカ リサーチ リミテッド ライアビリティ カンパニー フルベストラントのプロドラッグ
JP2023503898A (ja) * 2019-11-24 2023-02-01 カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ

Also Published As

Publication number Publication date
EP3801553A2 (en) 2021-04-14
WO2019224790A3 (en) 2020-01-16
JP7653092B2 (ja) 2025-03-28
EP3801553B1 (en) 2026-03-25
CA3101421A1 (en) 2019-11-28
JP2021525278A (ja) 2021-09-24
WO2019224790A2 (en) 2019-11-28
JP2024016210A (ja) 2024-02-06
CA3101421C (en) 2024-06-18
EP3801553A4 (en) 2022-04-27
AU2019274815B2 (en) 2024-11-07
AU2019274815A1 (en) 2021-01-21
US20210253626A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
JP7384903B2 (ja) フルベストラントのプロドラッグ
EP3325483B1 (en) Methods of preparing cytotoxic benzodiazepine derivatives
SK4672003A3 (en) Non-imidazole compounds, pharmaceutical composition comprising same and use thereof
WO2015121657A1 (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
JP2023503898A (ja) フルベストラントのプロドラッグ
US20230331751A1 (en) Stereoselective manufacture of selected purine phosphoramidates
WO2016082792A1 (zh) 一种阿比特龙衍生物及其制备方法和医药用途
WO2013007184A1 (zh) 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
WO2018229798A1 (en) Process for the preparation of bictegravir and intermediate thereof
JP2022545542A (ja) ピラゾール化合物、その製剤並びに化合物及び／又は製剤を使用する方法
CN118084881A (zh) Protac小分子及其药物组合物和应用
ES3034982T3 (en) Method of manufacturing a solid form of a bet bromodomain inhibitor
US10000527B2 (en) 11-substituted bile acid derivatives, process for the preparation thereof and use of these compounds as medicaments
JP7274415B2 (ja) ウイルス感染症および他の疾患を処置するためのピリミジンプロドラッグ
US20220235072A1 (en) Semi-synthetic analogues of epipolythiodioxopiperazine alkaloids
EP4093730B1 (en) Hdac degrader
AU2011311847A1 (en) Method of preparation of antiviral compounds and useful intermediates thereof
HK40029973B (en) Methods of preparing cytotoxic benzodiazepine derivatives
WO2021113922A1 (en) Improved method for preparing n-(benzenesulfonyl)-l-prolyl- l-o-(1-pyrrolidinylcarbonyl)tyrosine
WO2024020379A2 (en) Prodrugs, prodrug compositions and related methods
JPWO2018021517A1 (ja) ４−アルコキシ−３−トリフルオロメチルベンジルアルコールの製造方法
WO2021156811A1 (en) Novel processes for preparation of tezacaftor
HK1252323B (en) Methods of preparing cytotoxic benzodiazepine derivatives
HK1227870B (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
HK1227870A1 (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210125

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210122

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220113

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220524

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220516

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230816

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231010

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231109

R150 Certificate of patent or registration of utility model

Ref document number: 7384903

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S631 Written request for registration of reclamation of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313631

S633 Written request for registration of reclamation of name

Free format text: JAPANESE INTERMEDIATE CODE: R313633

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350